ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.70013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Abd El Kader Ait Tayeb und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de…. Hauptthemen laut MEDLINE: Methadone, Catechol O-Methyltransferase, Opioid-Related Disorders, Receptors, Opioid, mu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives, Université Paris 13.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background
Opioid use disorder (OUD) is an emerging and global public health concern, and its management remains inadequate, notably due to a lack of biomarkers, except for the CYP2B6 genetic polymorphisms.
Objectives
Hence, the aim of this study was to assess the influence of genetic polymorphisms of ABCB1, SLC22A1, COMT, and OPRM1 on biological parameters and clinical response in patients receiving methadone maintenance treatment (MMT).
Methods
A subgroup of 72 patients treated by MMT was genotyped for ABCB1 (rs1045642; rs2032582), SLC22A1 (rs12208357; rs72552763; rs113569197), COMT (rs4680), and OPRM1 (rs1799971) from Opioid PhArmacoLogy (OPAL), a clinical survey of patients suffering from OUD. Associations of these polymorphisms and both clinical and pharmacological (plasma methadone levels) responses were investigated.
Results
All polymorphisms tested were not associated with (R,S)‐methadone concentrations/doses (concentrations relative to doses), (R)‐methadone concentrations/doses nor (S)‐methadone concentrations/doses in bivariate analyses with codominant and recessive models. Also, polymorphisms tested were not related to clinical response (opiate cessation) during MMT in treated patients. The main limitations of our study were the sample size and the absence of polygenic analyses.
Conclusion
This study found no evidence to support the use of genotyping for polymorphisms in the ABCB1, SLC22A1, COMT, and OPRM1 genes in a clinical setting for the management of MMT in OUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, F-94275, France.
- Inserm, Physiologie et Physiopathologie Endocriniennes, Université Paris-Saclay, Le Kremlin-Bicêtre, 94276, France.
- CHU Nantes, CHU Tours, INSERM, MethodS in Patients-Centered Outcomes and HEalth Research, SPHERE, Nantes Université, Univ Tours, Nantes, 44000, France.
- CHU Nantes, Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, Nantes, 44000, France.
- UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, Nantes, 44000, France.
- CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France.
ORCID-Profile: Abd El Kader Ait Tayeb, Edouard-Jules Laforgue
Förderung
- Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives
- Université Paris 13
Zitieren
APA
Ait Tayeb, A. E. K., Laforgue, E. J., Schreck, B., Grall-Bronnec, M., Hardouin, J. B., Leboucher, J., OPAL Group, Victorri-Vigneau, C., & Verstuyft, C. (2025). ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70013
Vancouver
Ait Tayeb AEK, Laforgue EJ, Schreck B, Grall-Bronnec M, Hardouin JB, Leboucher J, et al. ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70013
BibTeX
@article{AitTayeb2025,
author = {Ait Tayeb, Abd El Kader and Laforgue, Edouard-Jules and Schreck, Benoit and Grall-Bronnec, Marie and Hardouin, Jean-Benoit and Leboucher, Juliette and OPAL Group, OPAL Group and Victorri-Vigneau, Caroline and Verstuyft, Céline},
title = {ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.70013}
}
EUVIMED